HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discus Dental/BriteSmile deal

This article was originally published in The Rose Sheet

Executive Summary

Zoom professional tooth whitening system marketer has signed a definitive agreement to purchase assets of BriteSmile's Associated Center business and "substantially all of BriteSmile's intellectual property" for $35 mil. in cash and the assumption of certain liabilities, firm announces Jan. 3. Expected to close in February, deal includes 5,000 independent dental offices in more than 75 countries, as well as the rights to manufacture, market and distribute BriteSmile whitening products and accessories to Associated Centers. BriteSmile will use proceeds "to reduce debt, to operate or sell its Spa Centers Business, and to continue to prosecute legal claims related to enforcement of certain proprietary teeth-whitening rights," according to the company. However, Discus Dental notes the firms "have also agreed to settle all outstanding litigation between the two companies"...

You may also be interested in...

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.

All About Value – Brexit Aside, UK Industry Sees Good Things Ahead For Healthtech Adoption

ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts